Allison Betof Warner joins the Stanford Cancer Institute
The Stanford Cancer Institute (SCI) is excited to welcome new faculty member Allison Betof Warner, MD, PhD, to the Department of Medicine, Division of Oncology.
At the SCI, she will serve as the director of the Melanoma Program and faculty leader of the Melanoma|Cutaneous Oncology Clinical Research Group in the SCI-Cancer Clinical Trials Office. She will oversee the research portfolio and facilitate the translational clinical research of the Melanoma Program.
Betof will also help build and oversee the Solid Tumor Cellular Therapy Program in collaboration with the Division of Blood and Marrow Transplantation and Cellular Therapy and the Center for Cancer Cell Cell Therapy. Additionally, she will serve as co-director of the Stanford Pigmented Lesion & Melanoma Program.
Betof received her MD and PhD from Duke University School of Medicine and completed her internal medicine residency at Massachusetts General Hospital (Harvard University) and medical oncology fellowship at Memorial Sloan Kettering Cancer Center, where she has been on the faculty since 2019.
Her research explores how the tumor microenvironment modulations affect immunotherapy, and she is the principal investigator of several trials focusing on immunotherapy-refractory melanoma. Betof Warner is internationally recognized for her expertise in brain/CNS metastasis and the use of novel cellular therapies. She was also recently named an awardee of the 2022 40 under 40 in cancer class.